0:00
My name is Nathan Tumey and I'm going to be discussing with you this morning a little bit
about some design challenges in the field of antibody-drug conjugates.
Just before we get going with that discussion let me just introduce myself.
I am a professor at Binghamton University in the
School of Pharmacy and Pharmaceutical Sciences; I teach medicinal chemistry here.
I've been here for about a year but prior to joining the faculty here at Binghamton,
I spent the last 15 years in the pharmaceutical industry, most recently
at Pfizer where I spent
about seven years in the field of developing antibody-drug conjugate.
So, my background is in chemistry,
my PhD is in organic chemistry and so I'm going to be sharing with you
my design perspective from the perspective of an organic chemist or a medicinal chemist.
So, realize that as we discuss antibody-drug conjugates,
it is a very broad field and I have
my own expertise and interests in it and I will share with you some
of the highlights of the way the field has been
developing over the last few years from the perspective of a medicinal chemist.
1:05
I'm going to introduce to you some ADC technology,
in general, just to get everybody up to the same speed and then we will
dig into four components of the design
of ADCs and in particular, discussing aspects of payload design,
linker design, conjugation chemistry as well
as factors to consider in the design of the antibody itself.
Then, we'll look at our crystal ball and see where the field is going,
what are some ways that the field is now
different than it was just a few years ago and where it's headed.
1:36
When I discuss ADCs with people the way I like to begin is with
this little picture and this is based on something Amazon presented a few years ago,
an idea or concept for delivering packages around major cities in the US using drones.
At a molecular level that's really
exactly what we're doing with an antibody-drug conjugate.
So, we have a delivery vehicle, which in our case is the antibody, which is kind of
an autonomous drone in many senses just
circulating through the body looking for a target of interest.
When it arrives at that target of interest,
it releases a payload and the payload is really what carries
the biological punch for this drug moiety or for the entity that we're trying to deliver.
So, the payload is what's going to be carrying out the interesting biology; whereas,
the delivery vehicle is simply delivering the payload to the right address.
